Manulife Financial has been an underperformer since the start of the tariff war, notes National Bank. Not only is the lifeco underperforming its peers and the Big-6 banks, it is also underperforming Asia-focused insurers. Analyst Gabriel Dechaine believes the latter group is relevant for comparison, given the growing impact of U.S.-China trade tensions on local stocks (e.g., Hang Seng down ~8% since April 2) and on economic outlooks in the region.
"We attribute MFC's recent underperformance to two possible factors: 1) investors viewing it as a more "beta sensitive" name, rather than a defensive one; and 2) concerns related to its Asia segment." Dechaine points out that Manulife's Asia segment is critical to the lifeco's 18%+ by 2027 ROE target, contributing nearly 50% of planned ROE expansion. Dechaine believes he market is discounting that the Asia segment may not contribute to MFC's ROE expansion as much as expected (or at all) due to U.S.-China trade tensions and calculates a 5% downside risk.
Reiterate Outperform, with a $50 target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.